Jonathan Jackson
Jonathan Jackson (D-IL) bought $15K-$50K of $AMZN (Amazon.com, Inc. - Common Stock (AMZN) [ST]) on Nov 27, 2024, part of 5 transactions in this filing (2 buys, 3 sells).
HillSignal flagged 2 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 4
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
2 flagsRep. Jackson purchased $15K-$50K in $AMZN on Nov 27, 2024 — 71 days before HR1062 (Growing and Preserving Innovation in America Act) was introduced, a bill that permanently locks in higher tax deductions for US multinationals like Amazon.
The same $15K-$50K AMZN purchase on Nov 27, 2024 also came 103 days before HR1990 (American Innovation and R&D Competitiveness Act), which would restore immediate R&D expensing — a change that directly benefits Amazon's large research operations.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $AMZN | Amazon.com, Inc. - Common Stock (AMZN) [ST] | $15K-$50K | $205.74 | $268.26 | +30.4% | Nov 27, 2024 |
| BUY | $CHD | Church & Dwight Company, Inc. Common Stock (CHD) [ST] | $15K-$50K | $107.26 | — | — | Nov 13, 2024 |
| SELL | $AMAT | Applied Materials, Inc. - Common Stock (AMAT) [ST] | $15K-$50K | $171.32 | — | — | Nov 27, 2024 |
| SELL | $REGN | Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) [ST] | $15K-$50K | — | — | — | Nov 13, 2024 |
| PARTIAL SELL | $REGN | Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) [ST] | $1K-$15K | — | — | — | Nov 1, 2024 |
Connected Legislative Activity
2 signalsThese bills and contracts share tickers or sectors with this filing's trades.
American Innovation and R&D Competitiveness Act of 2025
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
Growing and Preserving Innovation in America Act of 2025
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
Other Filings by Jonathan Jackson
Free — no credit card
Get the next Jackson trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.